Repare RP-3500-01 (Advanced Solid Tumors) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out the safest and most effective dose of the study drug (RP-3500) when it is given alone or in combination with talazoparib.

What is the Condition Being Studied?

Advanced Solid Tumors

Who Can Participate in the Study?

Adults with advanced cancer resistant to standard treatment with documented changes in certain genes.

For more information, contact the study team at 919-684-6342.

Age Group

Adults

What is Involved?

If you choose to join this study you will:

Go through a screening period to see if you qualify for the study
Take the study drug (RP-3500) by mouth 1 or 2 times a day according to the assigned schedule
Provide old tumor tissue
Have physical exams, blood and urine tests
Have imaging scans (CT and/or MRI)

Some people will also:

Take talazoparib by mouth once daily
Have tumor samples taken

Study Details

Full Title

Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with ATR inhibitor Sensitizing Mutations (TRESR Study)

Principal Investigator